EFG
CKPT

Ethos Financial Group’s Checkpoint Therapeutics CKPT Stock Holding History

Ethos Financial Group’s Portfolio CKPT Stock Details CKPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-12,060
Closed -$20.5K – 273
2023
Q3 		$20.5K Buy
+12,060
New +$27.4K 0.01% 178

Other funds holding CKPT

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BRWA
B. Riley Wealth Advisors Boca Raton, Florida $1.87B AUM 37.01% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
PAM
PVG Asset Management Golden, Colorado $173M AUM 64.51% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Ethos Financial Group's CKPT Position: Q4 2023 in Review

Ethos Financial Group sold out of Checkpoint Therapeutics (CKPT) in Q4 2023, closing a stake of 12,060 shares — an estimated $20.5K sold.

Ethos Financial Group first reported a position in CKPT in Q3 2023 and held it in 1 quarter. The position peaked at $20.5K in Q3 2023. 43 funds tracked by Wall St. Rank hold CKPT as of Q4 2023.

  • Ethos Financial Group reported no remaining Checkpoint Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Ethos Financial Group sold 12,060 Checkpoint Therapeutics shares in Q4 2023, an estimated $20.5K.
  • Ethos Financial Group first reported a position in Checkpoint Therapeutics in Q3 2023 and held it in 1 quarter.
  • Ethos Financial Group's Checkpoint Therapeutics position peaked at $20.5K in Q3 2023.
  • 43 funds tracked by Wall St. Rank held Checkpoint Therapeutics as of Q4 2023.

Based on Ethos Financial Group's 13F filing for Q4 2023, filed 7 Feb 2024.